Borski Fund invests in ShanX Medtech to accelerate the development of antimicrobial susceptibility diagnostics.

Borski Fund has completed an investment in ShanX Medtech. The Eindhoven-based medtech company is developing an innovative diagnostic platform for ultra-fast antimicrobial susceptibility testing, allowing doctors to determine the most effective treatment within one hour.

The investment is part of a overschreven seedronde van €15m, supplemented with public funding and European support, bringing ShanX's total to €24 million has secured funding. With this capital, ShanX will accelerate the final development, clinical validation, regulatory approval, and commercial market introduction of the SXM diagnostic platform, which is already attracting significant interest from healthcare and business partners.

Groundbreaking technology for a great challenge
ShanX's technology addresses one of the biggest challenges in global healthcare: antimicrobial resistance (AMR). ShanX Medtech is transforming the treatment of infections with ultra-fast, direct-from-specimen antimicrobial susceptibility testing (AST).

Using new chemical methods for monitoring micro-organism metabolism, ShanX extensive results within an hour with minimal user involvement. This is a groundbreaking improvement on current methods, which require multiple trained technicians and take days to yield usable results.

By enabling faster, evidence-based treatment decisions in both laboratory and point-of-care settings, the platform the potential to improve patient outcomes, reduce healthcare costs, combat the spread of AMR, and strengthen pandemic preparedness.

Sophia E. Shanko, Founder & CEO ShanX Medtech:
”We founded ShanX Medtech following one patient’s story, which highlighted the immense stakes involved when diagnostic results are delayed. Our vision is to empower every clinician to act decisively, armed with real-time diagnostic data. This funding brings us significantly closer to delivering ultra-fast AST directly to both laboratories and point-of-care settings; faster, simpler, and more accessible than ever before.”

Simone Brummelhuis, Partner at Borski Fund:
”We are delighted to announce this investment in Eindhoven-based ShanX Medtech. Following an extensive market analysis of innovations in antimicrobial resistance, ShanX's technology clearly emerged as best-in-class. While the company's initial market introduction strategy focuses on a clearly defined application for women's health in urinary tract infections, the underlying platform offers significant potential for a wide range of clinical indications. We are proud to support Sophia and her exceptional team in realising their ambitious vision. The oversubscribed funding round, combined with multiple multi-million euro commercial contracts, underscores both the strength of the technology and the proven commercial prowess of the founder.”

About Borski Fund
Borski Fund was founded in 2019 by Simone Brummelhuis and Laura Rooseboom and is based in Amsterdam. As a venture capital fund, Borski Fund focuses on bridging the funding gap for startups with female (co-)founders or companies developing innovative products and services for women. With a focus on sectors such as healthcare, circular energy and future society, Borski Fund promotes inclusive innovation and fair access to capital.

More information

• Want to know more about Borski Fund? Then check out the fund page or visit the fund website.
• Want to know more about ShanX Medtech? Read this here.
• Full press release (from ShanX Medtech)